Search results for: Multi-Indication Medicines
Filter search results
The New Global Economics of Vaccines: Will the Scientific Potential Be Realised?
1 January 2007
…vaccines. Some of these are emerging from GSK and the other two remaining large multinational producers; however, there are also new entrants into the vaccine market, including a couple of…
OHE at ISPOR Europe 2023
13 November 2023, 12:00am
…Frederick McElwee Poster time: 10:30-13:30 Discussion period: 12:30-13:30 Poster Session Health Technology Assessment of Multiple Myeloma Therapies: Value Demonstration and Value Recognition Challenges Nadine Henderson Poster time: 10:30-13:30 Discussion period:…
OHE’s AMR consultation response
21 November 2023
…antibiotics in late-stage development (Wellcome Trust, 2020; Butler et al., 2022). We have written previously on the causes of this underdevelopment. In brief, the persistent market failure is multifactorial, driven…
Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
9 June 2025
…efforts, attempts to formalise HTA governance have faced obstacles. Multiple legislative proposals for creating a national HTA agency have been introduced since the 2010s, but none have advanced through Congress….
Measuring Value with Pharmacoeconomics
26 May 2011
…provinces in Canada. Since then, the UK has established NICE (1999) and several other European countries request economic analyses for at least some new medicines, including Belgium, Finland, Ireland, Norway,…
In Memoriam: George Teeling Smith, OHE’s First Director
17 February 2013
…had threatened one major multinational with compulsory licensing of several of its drugs to force down prices. We were just beginning to understand how to achieve the right balance between…
Inconsistent Use of Cost-effectiveness Thresholds in NHS Scotland
12 December 2013
…Boards do not priorise their spending so as to maximize QALYs, but appear to be aiming instead at a multidimensional set of objectives. The Boards’ approaches to setting spending priorities,…
Pricing Variations Within and Across Countries: Gauging Efficiency
25 February 2014
This research explores which approaches to pricing can produce the greatest efficiency and access to medicines within and across countries. OHE collaborated on two articles published in the journal Health…
OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
…Husereau, University of Ottawa and UMIT, Joshua J. Carlson (VeriTech Corporation) (IP6, 11 Nov, 10:15–11:15) This panel addresses the implications of assessing the cost-effectiveness of emerging regenerative medicines, including gene…